Femilis LNG IUS
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intrauterine
-
Intended Duration:
- Long-Acting
- Development Stage: Phase III
- Developer(s)/researcher(s): Contrel Research, Belgium, APCOR R&M, Belgium
Details
- API: Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Ethylene Vinyl Acetate
- Regimen: 1 Insertion/5 Years
- MPT: Not Potential MPT
- Promising Attributes: Femilis is intended to maintain the positive side effects of approved hormonal IUDs while improving ease-of-training for providers and lowering risk of uterine perforation
Product Status
Developer's corporate website does not list product. No publications after 2016.
History
Developed by Dr. Dirk Wildemeersch in 1997, Femilis LNG-IUS & Femilis Slim were regularly evaluated in clinical contexts from 2002-2013